Healio reports that early results of an investigational device exemption clinical trial showed two prodisc C implants may be safe and effective for the treatment of symptomatic cervical disc disease at two levels compared with the Mobi-C implant at 24 months.

“Cervical total disc replacements have become their own standard of care,” said Celeste Abjornson, PhD, director of spinal research at HSS about results presented at the North American Spine Society Annual Meeting. “Studies like this show that the results, regardless of design, are promising and that there is going to be a paradigm shift in the marketplace. In the future, looking at studies like this will adjust a surgeon’s thinking to [consider patients for] a disc replacement first and then look at fusion as a secondary option, where in the past, surgeons looked at fusion because that was the classical standard.”

Read the full article at healio.com.